IKT
Inhibikase Therapeutics, Inc.
Key Financials
Net Income
$-48259189
↓ 75.4%
Operating Income
$-51974283
↓ 81.8%
Revenue
$0
↓ 100.0%
EPS (Diluted)
$-0.49
↑ 57.8%
Total Liabilities
$8.3M
↑ 122.3%
Total Assets
$181.2M
↑ 83.8%
Cash & Equivalents
$178.8M
↑ 216.5%
Shareholders' Equity
$172.9M
↑ 82.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/30/2026 | View on SEC |
| 4 | 6/30/2026 | View on SEC |
| 4 | 6/30/2026 | View on SEC |
| 4 | 6/30/2026 | View on SEC |
| 4 | 6/30/2026 | View on SEC |
| 4 | 6/30/2026 | View on SEC |
| 8-K | 6/29/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IKT |
| Company Name | Inhibikase Therapeutics, Inc. |
| CIK | 1750149 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (302) 295-3800 |